Puberty Precocious
Mostrando 1-12 de 44 artigos, teses e dissertações.
-
1. McCune-Albright syndrome - A case report with transmission electron microscopy
Abstract McCune - Albright syndrome is a genetic disease with cutaneous mosaicism caused by post-zygotic activating mutations in GNAS locus, it has a triad of fibrous bone dysplasia, café-au-lait macules and precocious puberty. We examined a 22-year-old female patient with café au lait spot in right side of the abdomen, with a chessboard - like distributio
Anais Brasileiros de Dermatologia. Publicado em: 2022
-
2. Central nervous system imaging in girls with central precocious puberty: when is necessary?
ABSTRACT Objectives The determinants of an increased risk of an organic pathology underlying central precocious puberty (CPP) in girls remain contentious. The present study aimed to determine the clinical and hormonal findings that can be used to differentiate organic and idiopathic CPP in girls as a screening method so that only those considered likely to
Arch. Endocrinol. Metab.. Publicado em: 2020-10
-
3. An Investigation of Hearing (250-20,000 Hz) in Children with Endocrine Diseases and Evaluation of Tinnitus and Vertigo Symptoms
Abstract Introduction Despite much advancement in medicine, endocrine and metabolic diseases remain an important cause of morbidity and even mortality in children. Objective The present study was planned to investigate the evaluation of hearing that also includes high frequencies, and the presence and degree of vertigo and tinnitus symptoms in pediatric
Int. Arch. Otorhinolaryngol.. Publicado em: 2020-06
-
4. Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment
ABSTRACT Objective To determine whether first-voided urinary LH (FV-ULH) – level measurement can adequately assess pubertal suppression as much as standard tests can. Subjects and methods The study group included patients with central precocious puberty and rapidly progressing early puberty who received up to 3 – 4 doses of GnRHa therapy monthly and
Arch. Endocrinol. Metab.. Publicado em: 2020-04
-
5. Challenges in monitoring GnRH analog treatment in central precocious puberty
ABSTRACT While the developed world is focusing on laying guidelines for selecting out cases of Asymptomatic primary hyperparathyroidism (PHPT) for surgical intervention and promoting minimal access surgery, the developing world is observing a change in disease spectrum from advanced symptomatic to lesser degree of symptomatic disease and not many with associ
Arch. Endocrinol. Metab.. Publicado em: 2020-04
-
6. Clinical and Laboratory Parameters of Gonadotropin-Releasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that det
Clinics. Publicado em: 07/11/2019
-
7. Pioneering studies on monogenic central precocious puberty
ABSTRACT Pubertal timing in humans is determined by complex interactions including hormonal, metabolic, environmental, ethnic, and genetic factors. Central precocious puberty (CPP) is defined as the premature reactivation of the hypothalamic-pituitary-gonadal axis, starting before the ages of 8 and 9 years in girls and boys, respectively; familial CPP is def
Arch. Endocrinol. Metab.. Publicado em: 22/08/2019
-
8. Induction of puberty and synchronization of estrus in gilts with eCG and GnRH
ABSTRACT In this study, we investigated the effects of eCG and GnRH on the induction of puberty in prepubertal gilts and evaluated the pregnancy rate and litter size in these females. Thirty 140-day-old gilts with an average weight of 80 kg were randomly divided into two treatments: hormonal treatment (n = 15): 1000 IU of eCG and 50 μg of GnRH; and control
R. Bras. Zootec.. Publicado em: 29/11/2018
-
9. Applicability of a novel mathematical model for the prediction of adult height and age at menarche in girls with idiopathic central precocious puberty
OBJECTIVES: Unfavorable predicted adult height and psychosocial inadequacy represent parameters used to guide therapeutic intervention in girls with central precocious puberty. Gonadotropin-releasing hormone analog is the first-line treatment. The aim of this study was to compare two methods used to predict adult height and assess a validated tool for predi
Clinics. Publicado em: 26/07/2018
-
10. A boy with Prader-Willi syndrome: unmasking precocious puberty during growth hormone replacement therapy
SUMMARY Prader-Willi syndrome (PWS) is a genetic disorder frequently characterized by obesity, growth hormone deficiency, genital abnormalities, and hypogonadotropic hypogonadism. Incomplete or delayed pubertal development as well as premature adrenarche are usually found in PWS, whereas central precocious puberty (CPP) is very rare. This study aimed to repo
Arch. Endocrinol. Metab.. Publicado em: 25/08/2016
-
11. Central precocious puberty: revisiting the diagnosis and therapeutic management
ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of
Arch. Endocrinol. Metab.. Publicado em: 2016-04
-
12. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM)
Objective To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment. Subjects and methods Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/mon
Arch. Endocrinol. Metab.. Publicado em: 25/09/2015